By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


SEARCH JOBS

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

YEAR FOUNDED:

July 16, 1993

LEADERSHIP:

Founder: Mark Brann

CEO: Stephen Davis

CMO (Medical): Randall Owen

JOBS:

Please click here for Acadia Pharma job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


PRODUCTS:

All Products


Key Statistics


Email: lbarthelemy@acadia-pharm.com
Ownership: Public

Web Site: Acadia
Employees: 140
Symbol: ACAD
 




Segment
Drug Discovery

Collaborations

Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.





Company News
Acadia (ACAD) Reports First Quarter 2017 Financial Results 5/10/2017 7:11:39 AM
Acadia (ACAD) To Announce First Quarter 2017 Financial Results On May 9, 2017 5/2/2017 7:31:39 AM
Acadia (ACAD) Announces Appointment Of Michael J. Yang As Executive Vice President, Chief Commercial Officer 3/30/2017 8:27:30 AM
Acadia (ACAD) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2016 3/1/2017 6:56:55 AM
Acadia (ACAD) To Announce Fourth Quarter And Full Year 2016 Financial Results On February 28, 2017 2/21/2017 8:17:23 AM
Always a Bridesmaid, Never a Bride: Acadia (ACAD) Moves Higher on Takeover Speculation 2/6/2017 6:05:59 AM
Acadia (ACAD) Stock Screams Upward; Primary Endpoint Met in Phase II Study of Pimavanserin for Alzheimer’s 12/20/2016 7:07:39 AM
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder 12/1/2016 7:59:07 AM
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia 11/15/2016 11:08:33 AM
Acadia (ACAD) Reports Third Quarter 2016 Financial Results 11/8/2016 10:44:17 AM
12345678910...
//-->